Bristol Myers Squibb (BMS) has agreed to acquire its longtime cell therapy partner 2seventy bio in a deal valued at $286m. Announced after markets closed on 10 March, the $5-per-share offer ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the ...

Net of the Cambridge, Massachusetts-based biotech's cash reserves, the deal is costing BMS just $102 million. 2seventy bio worked with BMS on the development of BCMA-directed CAR-T therapy Abecma ...

According to analysts at BMO Capital Markets, non-obstructive hypertrophic cardiomyopathy would have meant a $1.3 billion ...

The FDA approved the use of Opdivo with Yervoy in front-line colorectal cancer, while a Manhattan court junked a class action ...

Bristol Myers Squibb (BMS) plans to buy out its partner in developing the blockbuster multiple myeloma drug Abecma ® (idecabtagene vicleucel), by agreeing to acquire 2seventy bio for ...

The deal – which is worth up to $905 million with an upfront fee of $90 million – gives BMS full control of BridgeBio's experimental SHP2 inhibitor BBP-398, which is already in a phase 1 trial ...

2seventy bio investors were understandably happy this past week when Bristol Myers Squibb (BMS) agreed to acquire its partner in developing the blockbuster multiple myeloma drug Abecma ...

The appointment of Dr. Banerjee culminates Artiva’s efforts to build a seasoned development team with strong expertise in autoimmunity and cell therapy that includes the following recent additions: ...

At last week’s American Chemical Society Spring meeting, Bristol Myers Squibb Co. discussed the development of a potent, orally bioavailable and highly selective cereblon (CRBN)-mediated ...